Prosecution Insights
Last updated: November 19, 2026
Application No. 18/496,404

PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME

Non-Final OA §102
Filed
Oct 27, 2023
Examiner
WARD, PAUL V
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Theravance Biopharma R&D IP LLC
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
1427 granted / 1714 resolved
+23.3% vs TC avg
Minimal -12% lift
Without
With
+-12.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
72 currently pending
Career history
1765
Total Applications
across all art units

Statute-Specific Performance

§101
5.5%
-34.5% vs TC avg
§103
20.3%
-19.7% vs TC avg
§102
18.7%
-21.3% vs TC avg
§112
42.7%
+2.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1714 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restrictions Applicant’s election without traverse of Group VIII in the reply filed on August 31, 2026, is acknowledged. Groups I-VII are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant reserved the right to file a divisional or continuation application to the non-elected subject matter. An action on the merits on claim 19 (Group I) is contained herein. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 79-81 and 83-94 are rejected under 35 U.S.C. 102 as being anticipated by Sabine et al. (US Pub. 2007/0298112). Applicant claims the following composition: PNG media_image1.png 132 820 media_image1.png Greyscale PNG media_image2.png 505 513 media_image2.png Greyscale PNG media_image3.png 520 582 media_image3.png Greyscale PNG media_image4.png 586 632 media_image4.png Greyscale This reference discloses Applicant’s pharmaceutical compositions on pages 2 (paragraphs [0028]-[0029]), 5, 6 (paragraphs [0071]-[0073]), 14 (Example 1), 1s 15-16 (Examples 8-11) and figures 18 and 23. (See Abstract Tables, Examples and page 23 and entire document). The pharmaceutical compositions read on the instant claims. Since this reference teaches the exact pharmaceutical compositions, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102. Conclusion Claim 19 is pending in this application. Claim 19 is rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL V WARD/ Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Oct 27, 2023
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797387
LEMBOREXANT FOR TREATING SLEEP ISSUES
4y 11m to grant Granted Nov 17, 2026
Patent 12799135
CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF
4y 4m to grant Granted Nov 17, 2026
Patent 12797394
MNTBAP AND M(III)N-SUBSTITUTED PYRIDYLPORPHYRINS(MNPS)FOR USE IN REVERSING SEPSIS-INDUCED MICROGLIAL CELLS ALTERATIONS AND/OR FOR TREATING SEPSIS OR SEPSIS-ASSOCIATED ENCEPHALOPATHY
3y 2m to grant Granted Nov 17, 2026
Patent 12790316
1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE
4y 0m to grant Granted Nov 10, 2026
Patent 12788818
HYALURONIC ACID-BASED FORMULATIONS FOR TREATMENT AND PREVENTION OF OCULAR HYPERTENSION AND GLAUCOMA
3y 10m to grant Granted Nov 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
71%
With Interview (-12.2%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1714 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month